PDF herunterladen
Pharmacopsychiatry 2010; 43(2): 50-57
DOI: 10.1055/s-0029-1239539
Original Paper

© Georg Thieme Verlag KG Stuttgart · New York

Effect of Aripiprazole on Cognition in the Treatment of Patients with Schizophrenia

M. Riedel1 , I. Spellmann1 , R. Schennach-Wolff1 , R. Musil1 , S. Dehning1 , A. Cerovecki1 , M. Opgen-Rhein1 , J. Matz1 , F. Seemüller1 , M. Obermeier1 , E. Severus1 , R. R. Engel1 , N. Müller1 , H.-J. Möller1
  • 1Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University, Munich, Germany
Weitere Informationen

Publikationsverlauf

received 16.04.2009 revised 30.07.2009

accepted 08.09.2009

Publikationsdatum:
10. Dezember 2009 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Background: The aim of this study was to assess the cognitive effects of aripiprazole in inpatients with schizophrenia.

Methods: This was an investigator-initiated, open label eight-week trial evaluating 56 inpatients with the DSM-IV diagnosis of schizophrenia. Efficacy was assessed weekly using the Positive and Negative Syndrome Scale (PANSS) and tolerability was assessed each week using the Udvalg for Klinske Undersogelser side effect rating scale (UKU). Cognitive function was assessed at baseline, week 4 and week 8.

Results: Aripiprazole showed significant improvement in PANSS total score and all subscores between baseline and endpoint visit. The substance was very well tolerated. Patients improved significantly in verbal memory, reaction time and reaction quality/attention from baseline to week eight. Furthermore, mean z-values of individual cognitive domains summarized in a global cognitive index improved significantly from baseline to week eight.

Discussion: Our results suggest that aripiprazole provides a valuable treatment option for patients with schizophrenia.

References

  • 1 Akdede BB, nil Yagcioglu AE, Alptekin K. et al . A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition.  J Clin Psychiatry. 2006;  67 1912-1919
    CrossrefPubMedGoogle Scholar
  • 2 American Psychiatric Association .Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association, Washington DC 1994
    PubMed
  • 3 Andersen B. Regression toward the mean. In: Methodological errors in medical research. Blackwell Scientific Publications, London 1990 pp 98-108
    PubMedGoogle Scholar
  • 4 Beasley CM, Tollefson G, Tran P. et al . Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.  Neuropsychopharmacology. 1996;  14 111-123
    CrossrefPubMedGoogle Scholar
  • 5 Bilder RM, Goldman RS, Volavka J. et al . Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.  Am J Psychiatry. 2002;  159 1018-1028
    CrossrefPubMedGoogle Scholar
  • 6 Bilder RM, Reiter G, Bates J. et al . Cognitive development in schizophrenia: follow-back from the first episode.  J Clin Exp Neuropsychol. 2006;  28 270-282
    PubMedGoogle Scholar
  • 7 Burris KD, Molski TF, Xu C. et al . Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors.  J Pharmacol Exp Ther. 2002;  302 381-389
    CrossrefPubMedGoogle Scholar
  • 8 Cording C. Conceptual aspects in development and implementation of basic psychiatric documentation.  Psychiatr Prax. 1998;  25 175-178
    PubMedGoogle Scholar
  • 9 Davidson M, Galderisi S, Weiser M. et al . Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST).  Am J Psychiatry. 2009;  166 675-682
    CrossrefPubMedGoogle Scholar
  • 10 Dossenbach M, rango-Davila C, Silva IH. et al . Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.  J Clin Psychiatry. 2005;  66 1021-1030
    CrossrefPubMedGoogle Scholar
  • 11 Fujii DE, Wylie AM, Nathan JH. Neurocognition and long-term prediction of quality of life in outpatients with severe and persistent mental illness.  Schizophr Res. 2004;  69 67-73
    CrossrefPubMedGoogle Scholar
  • 12 Gold JM, Carpenter C, Randolph C. et al . Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia.  Arch Gen Psychiatry. 1997;  54 159-165
    CrossrefPubMedGoogle Scholar
  • 13 Goldberg TE, Goldman RS, Burdick KE. et al . Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?.  Arch Gen Psychiatry. 2007;  64 1115-1122
    CrossrefPubMedGoogle Scholar
  • 14 Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia?.  Am J Psychiatry. 1996;  153 321-330
    CrossrefPubMedGoogle Scholar
  • 15 Gutbrod K, Cohen R, Mager B. et al . Coding and recall of categorized material in aphasics.  J Clin Exp Neuropsychol. 1989;  11 821-841
    PubMedGoogle Scholar
  • 16 Guy W. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology National Institute of Mental Health, Rockville, MD revised 1976
    PubMed
  • 17 Harvey PD. Ziprasidone and cognition: the evolving story.  J Clin Psychiatry. 2003;  64 ((Suppl 19)) 33-39
    PubMedGoogle Scholar
  • 18 Hawkins KA. Memory deficits in patients with schizophrenia: preliminary data from the Wechsler Memory Scale-Third Edition support earlier findings. J Psychiatry Neurosci. 1999 24: 341-347
    PubMedGoogle Scholar
  • 19 Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence.  Neuropsychology. 1998;  12 426-445
    CrossrefPubMedGoogle Scholar
  • 20 Ichikawa J, Dai J, O IA. et al . Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum.  Neuropsychopharmacology. 2002;  26 325-339
    CrossrefPubMedGoogle Scholar
  • 21 Keefe RS, Bilder RM, Davis SM. et al . Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.  Arch Gen Psychiatry. 2007;  64 633-647
    CrossrefPubMedGoogle Scholar
  • 22 Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the positive and negative syndrome scale for schizophrenics.  Psychiatry Res. 1998;  23 99-110
    PubMedGoogle Scholar
  • 23 Keefe RS, Roitman SE, Harvey PD. et al . A pen-and-paper human analogue of a monkey prefrontal cortex activation task: spatial working memory in patients with schizophrenia.  Schizophr Res. 1995;  17 25-33
    CrossrefPubMedGoogle Scholar
  • 24 Keefe RS, Silva SG, Perkins DO. et al . The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis.  Schizophr Bull. 1999;  25 201-222
    PubMedGoogle Scholar
  • 25 Keefe RS, Sweeney JA, Gu H. et al . Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.  Am J Psychiatry. 2007;  164 1061-1071
    CrossrefPubMedGoogle Scholar
  • 26 Kern RS, Green MF, Cornblatt BA. et al . The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine.  Psychopharmacology (Berl). 2006;  187 312-320
    CrossrefPubMedGoogle Scholar
  • 27 Lindenmayer JP, Khan A, Iskander A. et al . A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.  J Clin Psychiatry. 2007;  68 368-379
    CrossrefPubMedGoogle Scholar
  • 28 Lingjaerde O, Ahlfors UG, Bech P. et al . The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients.  Acta Psychiatr Scand Suppl. 1987;  334 1-100
    PubMedGoogle Scholar
  • 29 Millan MJ. Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors.  J Pharmacol Exp Ther. 2000;  295 853-861
    PubMedGoogle Scholar
  • 30 Milev P, Ho BC, Arndt S. et al . Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up.  Am J Psychiatry. 2005;  162 495-506
    CrossrefPubMedGoogle Scholar
  • 31 Purdon SE, Jones BD, Stip E. et al . The Canadian Collaborative Group for research in schizophrenia  Arch Gen Psychiatry. 2000;  57 249-258
    CrossrefPubMed
  • 32 R Development Core Team .A language and environment for statistical computing. Foundation for Statistical Computing, Vienna, Austria 2008
    PubMed
  • 33 Reitan RM. Validity of the trailmaking test as an indication of organic brain damage.  Percept Mot Skills. 1958;  8 271-276
    CrossrefPubMedGoogle Scholar
  • 34 Rey A. Lexamen clinique en psychologie. Presse Universitaire de France, Paris 1958
    PubMed
  • 35 Riedel M, Muller N, Spellmann I. et al . Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia.  Eur Arch Psychiatry Clin Neurosci. 2007;  257 402-412
    CrossrefPubMedGoogle Scholar
  • 36 Riedel M, Spellmann I, Strassnig M. et al . Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.  Eur Arch Psychiatry Clin Neurosci. 2007;  257 360-370
    CrossrefPubMedGoogle Scholar
  • 37 Saykin AJ, Gur RC, Gur RE. et al . Neuropsychological function in schizophrenia. Selective impairment in memory and learning.  Arch Gen Psychiatry. 1991;  48 618-624
    CrossrefPubMedGoogle Scholar
  • 38 Spreen O, Benton AL. Comparative studies of some psychological tests for cerebral damage.  J Nerv Ment Dis. 1965;  140 323-333
    PubMedGoogle Scholar
  • 39 Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, “Goldilocks” actions at dopamine receptors.  J Clin Psychiatry. 2001;  62 841-842
    CrossrefPubMedGoogle Scholar
  • 40 Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action.  J Clin Psychiatry. 2001;  62 923-924
    CrossrefPubMedGoogle Scholar
  • 41 Tabares-Seisdedos R, Balanza-Martinez V, Sanchez-Moreno J. et al . Neurocognitive and clinical predictors of functional outcome in patients with schizophrenia and bipolar I disorder at one-year follow-up.  J Affect Disord. 2008;  109 286-299
    CrossrefPubMedGoogle Scholar
  • 42 Wiebel B, Happe A, Peikara F. Das neuropsychologische Diagnostikprogramm TESTBAT. Psymed, Dulmen 1995
    PubMed
  • 43 Wittorf A, Sickinger S, Wiedemann G. et al . Neurocognitive effects of atypical and conventional antipsychotic drugs in schizophrenia: a naturalistic 6-month follow-up study.  Arch Clin Neuropsychol. 2008;  23 271-282
    CrossrefPubMedGoogle Scholar
  • 44 Woodward ND, Purdon SE, Meltzer HY. et al . (2005) A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia.  Int J Neuropsychopharmacol. 2005;  8 457-472
    CrossrefPubMedGoogle Scholar

Correspondence

R. Schennach-WolffMD 

Department of Psychiatry

Ludwig-Maximilians-University

Nussbaumstraße 7

80336 Munich

Germany

Telefon: +49/89/5160 58 69

Fax: +49/89/5160 58 57

eMail: Rebecca.Schennach-Wolff@med.uni-muenchen.de

      >